Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study
Journal of the European Academy of Dermatology and Venereology · 2025-06 · 39 (6) · 1174-1184
DOI: 10.1111/jdv.20605 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 27.03.2025. Verfasst von B King und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Physicians of Connecticut, Fairfield, Connecticut, USA. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Inc, Pfizer.
Abstract (Originalsprache)
Background
Etrasimod, an oral, selective sphingosine 1‐phosphate 1, 4 and 5 receptor modulator approved for the treatment of ulcerative colitis, has been studied in immune‐mediated inflammatory diseases, including alopecia areata (AA).
Objectives
To evaluate the efficacy and safety of etrasimod in adults with moderate to severe AA.
Methods
This Phase 2, randomized, double‐blind, placebo‐controlled trial included patients (aged ≥18 years) with moderate to severe AA, defined as a Severity of Alopecia Tool (SALT) score of ≥25. Patients were sequentially enrolled into two cohorts. Cohort 1 included patients (SALT score of ≥50) randomized 2:1 to etrasimod 2 mg or placebo. Cohort 2 included patients (SALT score ≥25 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dermatology Physicians of Connecticut, Fairfield, Connecticut, USA.
- Department of Dermatology and Dermatopathology, UCI School of Medicine, Irvine, California, USA.
- Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
- Pfizer China R&D Center, Shanghai, China.
- Pfizer Inc, New York, New York, USA.
Förderung
- Pfizer Inc
- Pfizer
Zitieren
APA
King, B., Mesinkovska, N., Senna, M., Luo, X., Minkiewicz, J., & Selfridge, A. (2025). Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study. Journal of the European Academy of Dermatology and Venereology, 39(6), 1174-1184. https://doi.org/10.1111/jdv.20605
Vancouver
King B, Mesinkovska N, Senna M, Luo X, Minkiewicz J, Selfridge A. Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study. Journal of the European Academy of Dermatology and Venereology. 2025;39(6):1174-1184. doi:10.1111/jdv.20605
BibTeX
@article{King2025,
author = {King, B and Mesinkovska, N and Senna, M and Luo, X and Minkiewicz, J and Selfridge, A},
title = {Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
volume = {39},
number = {6},
pages = {1174--1184},
doi = {10.1111/jdv.20605}
}
EUVIMED